Etoposide and Cisplatin Dosing in SCLC
For small-cell lung cancer, use cisplatin 75 mg/m² on day 1 with etoposide 100 mg/m² on days 1,2, and 3, repeated every 21 days for 4 cycles in limited-stage disease or 4-6 cycles in extensive-stage disease. 1
Limited-Stage SCLC (with concurrent radiotherapy)
The NCCN 2026 guidelines provide clear Category 1 recommendations for dosing during concurrent chemoradiotherapy 1:
Preferred Regimens:
- Cisplatin 75 mg/m² day 1 + Etoposide 100 mg/m² days 1,2,3 (every 21-28 days)
- Cisplatin 60 mg/m² day 1 + Etoposide 120 mg/m² days 1,2,3
- Alternative: Cisplatin 25 mg/m² days 1,2,3 + Etoposide 100 mg/m² days 1,2,3
Treatment duration: 4 cycles during concurrent radiotherapy 1, 2
The ASCO-Ontario Health guideline confirms cisplatin 60-80 mg/m² on day 1 with etoposide 100-120 mg/m² on days 1,2, and 3 as standard dosing, emphasizing attempts to minimize dose reductions especially during the first two cycles 2.
Extensive-Stage SCLC
Preferred Regimens (with immunotherapy):
- Cisplatin 75-80 mg/m² day 1 + Etoposide 80-100 mg/m² days 1,2,3 + Durvalumab 1500 mg day 1 every 21 days × 4 cycles (Category 1) 1
- Carboplatin AUC 5 day 1 + Etoposide 100 mg/m² days 1,2,3 + Atezolizumab 1200 mg day 1 every 21 days × 4 cycles (Category 1) 1
Without Immunotherapy:
- Cisplatin 75 mg/m² day 1 + Etoposide 100 mg/m² days 1,2,3
- Cisplatin 80 mg/m² day 1 + Etoposide 80 mg/m² days 1,2,3
Treatment duration: 4 cycles recommended, though some patients may receive up to 6 cycles based on response and tolerability 1
Dose Adjustments
Renal Impairment:
The FDA label provides specific guidance for etoposide dose reduction 3:
| Creatinine Clearance | Etoposide Dose |
|---|---|
| >50 mL/min | 100% of dose |
| 15-50 mL/min | 75% of dose |
| <15 mL/min | Further reduction required |
Cisplatin contraindication: Cisplatin should not be used with creatinine clearance <60 mL/min according to German SmPC 4. In such cases, substitute carboplatin AUC 5-6 1, 2.
Hepatic Impairment:
While specific hepatic dosing adjustments are not detailed in the guidelines, patients with low serum albumin are at increased risk for etoposide-associated toxicities and require careful monitoring 3.
Age Considerations:
No specific dose reductions are recommended based on age alone. However, elderly patients (≥65 years) experience increased frequency of WHO Grade III-IV leukopenia and should be monitored closely 3. The standard doses remain appropriate with careful toxicity monitoring.
Administration Details
Etoposide administration: Must be diluted to 0.2-0.4 mg/mL and infused over 30-60 minutes to prevent hypotension 3. Rapid IV injection is contraindicated.
Cisplatin administration: Standard hydration protocols should be followed to minimize nephrotoxicity.
Critical Pitfalls to Avoid
Do NOT use myeloid growth factors during concurrent chemoradiotherapy plus RT (Category 1 recommendation against GM-CSF use) 1
Do NOT give rapid IV etoposide - hypotension risk requires 30-60 minute infusion 3
Do NOT continue beyond 4 cycles in limited-stage disease - no survival benefit demonstrated for extending to 6 cycles 2
Do NOT use cisplatin if creatinine clearance <60 mL/min - switch to carboplatin 4
Minimize dose reductions during first two cycles when possible, as this impacts outcomes 2
Carboplatin Substitution
When cisplatin is contraindicated (renal impairment, neuropathy, ototoxicity, or hypersensitivity), carboplatin AUC 5-6 may be substituted with etoposide 100 mg/m² days 1,2,3 1, 2. While one randomized trial showed no significant OS difference between cisplatin/etoposide and carboplatin/etoposide regimens, cisplatin remains preferred when tolerable 2.